Opinion|Videos|February 10, 2025
Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems
Author(s)Debra Fromer, MD
An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram-negative Enterobacterales,” including its objective, design, methodology, results, and key takeaways, and discusses how this data impacts the treatment of inpatient uncomplicated UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly describe the study “Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-spectrum β-lactamase-phenotype Gram-negative Enterobacterales.”
- What was the objective of this study?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. How does this data impact how you treat inpatient UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales?
Advertisement
Related to this article
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Progress Drives Down US Cancer Death Rates
2
All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected
3
Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care
4
Semaglutide Adherence Falls Once Out-of-Pocket Costs Top $75 a Month
5